Loss-of-function variants in ANGPTL3, identified in large-scale studies, are associated with familial combined hypolipidemia (FCH) and reduced coronary artery disease (CAD) risk; however, no link has been established between gain-of-function mutations in ANGPTL3 and dyslipidemia, such as familial combined hyperlipidemia (FCHL) [56]. Here, ANGPTL3 is linked to metabolic syndrome.